Impact of serum C-reactive protein level on the prognosis of patients with hepatocellular carcinoma undergoing TACE
2
조회
0
다운로드
2
인용
0
참고문헌
키워드
초록
Background/Aims: The aim of this study was to determine the relationship between serum CRP levels and the prognosis of hepatocellular carcinoma (HCC) patients. Methods: HCC patients who underwent the first session of transcatheter arterial chemoembolization (TACE) between January 2005 and December 2009 (n=211) were analyzed retrospectively. The patients were divided into two groups:high C-reactive protein (CRP; ≥1 mg/dL, n=51) and low CRP (<1 mg/dL, n=160). They were followed for a mean of 22.44 months and their clinicoradiological variables and overall survival were compared. Results: There were significant differences between the two groups in regard to tumor type, tumor-progression-free survival, 10-month mortality, white blood cell (WBC) count, tumor size, and TNM stage. Multivariate analysis revealed that a high serum CRP level was independently associated with tumor size and tumor type. Subgroup analysis of CRP groups according to tumor size demonstrated that a high serum level of CRP was significantly associated with poorly defined (diffuse) tumor type in the tumor size <5 cm group [hazard ratio (HR)=4.81, P=0.018]. A Lipiodol dose exceeding 7 mL (HR=5.55, P=0.046) and the 10-month mortality (HR=7.693, P=0.004) were significantly associated with high serum CRP level in the group of patients with a tumor size of ≥5 cm. In addition, subgroup analysis of matched CRP according to TNM stage revealed that elevated serum CRP was independently associated with tumor type, WBC count, and tumorprogression-free survival. Conclusions: A high serum CRP level is associated with large tumors and a poorly defined tumor type, and is significantly associated with 10-month mortality in patients with large HCC (size ≥5 cm) who undergo TACE. (Clin Mol Hepatol 2013;19:70-77)
Abstract
Background/Aims: The aim of this study was to determine the relationship between serum CRP levels and the prognosis of hepatocellular carcinoma (HCC) patients. Methods: HCC patients who underwent the first session of transcatheter arterial chemoembolization (TACE) between January 2005 and December 2009 (n=211) were analyzed retrospectively. The patients were divided into two groups:high C-reactive protein (CRP; ≥1 mg/dL, n=51) and low CRP (<1 mg/dL, n=160). They were followed for a mean of 22.44 months and their clinicoradiological variables and overall survival were compared. Results: There were significant differences between the two groups in regard to tumor type, tumor-progression-free survival, 10-month mortality, white blood cell (WBC) count, tumor size, and TNM stage. Multivariate analysis revealed that a high serum CRP level was independently associated with tumor size and tumor type. Subgroup analysis of CRP groups according to tumor size demonstrated that a high serum level of CRP was significantly associated with poorly defined (diffuse) tumor type in the tumor size <5 cm group [hazard ratio (HR)=4.81, P=0.018]. A Lipiodol dose exceeding 7 mL (HR=5.55, P=0.046) and the 10-month mortality (HR=7.693, P=0.004) were significantly associated with high serum CRP level in the group of patients with a tumor size of ≥5 cm. In addition, subgroup analysis of matched CRP according to TNM stage revealed that elevated serum CRP was independently associated with tumor type, WBC count, and tumorprogression-free survival. Conclusions: A high serum CRP level is associated with large tumors and a poorly defined tumor type, and is significantly associated with 10-month mortality in patients with large HCC (size ≥5 cm) who undergo TACE. (Clin Mol Hepatol 2013;19:70-77)
참고문헌 (27)
- Yang JD, "Hepatocellular carcinoma: A global view", Nat Rev Gastroenterol Hepatol, 7, pp.448~458 (2010)
- Mazzaferro V, "Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis", N Engl J Med, 334, pp.693~699 (1996)
- Llovet JM, "Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial", Lancet, 359, pp.1734~1739 (2002)
- Balkwill F, "Inflammation and cancer: back to Virchow?", Lancet, 357, pp.539~545 (2001)
- Heikkilä K, "A systematic review of the association between circulating concentrations of C reactive protein and cancer", J Epidemiol Community Health, 61, pp.824~833 (2007)
- Chiang AC, "Molecular basis of metastasis", N Engl J Med, 359, pp.2814~2823 (2008)
- Okamoto M, "Interleukin-6 as a paracrine and autocrine growth factor in human prostatic carcinoma cells in vitro", Cancer Res, 57, pp.141~146 (1997)
- Miki S, "Interleukin-6 (IL-6) functions as an in vitro autocrine growth factor in renal cell carcinomas", FEBS Lett, 250, pp.607~610 (1989)
- Miki C, "C-reactive protein as a prognostic variable that reflects uncontrolled upregulation of the IL-1-IL-6 network system in colorectal carcinoma", Dig Dis Sci, 49, pp.970~976 (2004)
- Nozoe T, "Immunohistochemical expression of C-reactive protein in squamous cell carcinoma of the esophagus - significance as a tumor marker", Cancer Lett, 192, pp.89~95 (2003)
- Fujikawa K, "Serum Creactive protein level and the impact of cytoreductive surgery in patients with metastatic renal cell carcinoma", J Urol, 162, pp.1934~1937 (1999)
- Nozoe T, "Significance of preoperative elevation of serum C-reactive protein as an indicator for prognosis in colorectal cancer", Am J Surg, 176, pp.335~338 (1998)
- Nozoe T, "Significance of preoperative elevation of serum C-reactive protein as an indicator of prognosis in esophageal carcinoma", Am J Surg, 182, pp.197~201 (2001)
- Rashid SA, "Plasma protein profiles and prognosis in gastric cancer", Br J Cancer, 45, pp.390~394 (1982)
- Ueno H, "Prognostic factors in patients with metastatic pancreatic adenocarcinoma receiving systemic chemotherapy", Oncology, 59, pp.296~301 (2000)
- Pierce BL, "Elevated biomarkers of inflammation are associated with reduced survival among breast cancer patients", J Clin Oncol, 27, pp.3437~3444 (2009)
- Hashimoto K, "The impact of preoperative serum C-reactive protein on the prognosis of patients with hepatocellular carcinoma", Cancer, 103, pp.1856~1864 (2005)
- Kinoshita A, "Pretreatment serum C-reactive protein level predicts poor prognosis in patients with hepatocellular carcinoma", Med Oncol, 29, pp.2800~2808 (2012)
- Nagaoka S, "Serum C-reactive protein levels predict survival in hepatocellular carcinoma", Liver Int, 27, pp.1091~1097 (2007)
- Takayasu K, "Comparison of CT findings with resected specimens after chemoembolization with iodized oil for hepatocellular carcinoma", AJR Am J Roentgenol, 175, pp.699~704 (2000)
- Kanematsu T, "A 5-year experience of lipiodolization: selective regional chemotherapy for 200 patients with hepatocellular carcinoma", Hepatology, 10, pp.98~102 (1989)
- McMillan DC, "Systemic inflammatory response predicts survival following curative resection of colorectal cancer", Br J Surg, 90, pp.215~219 (2003)
- Scott HR, "The systemic inflammatory response, weight loss, performance status and survival in patients with inoperable non-small cell lung cancer", Br J Cancer, 87, pp.264~267 (2002)
- Chun JM, "Prognostic factors after early recurrence in patients who underwent curative resection for hepatocellular carcinoma", J Surg Oncol, 103, pp.148~151 (2011)
- Mahmoud FA, "The role of C-reactive protein as a prognostic indicator in advanced cancer", Curr Oncol Rep, 4, pp.250~255 (2002)
- Lin ZY, "Role of serum C-reactive protein as a marker of hepatocellular carcinoma in patients with cirrhosis", J Gastroenterol Hepatol, 15, pp.417~421 (2000)
- Raoul JL, "Evolving strategies for the management of intermediate-stage hepatocellular carcinoma: available evidence and expert opinion on the use of transarterial chemoembolization", Cancer Treat Rev, 37, pp.212~220 (2011)